Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: Comparison of International Harmonization Project (IHP), Gallamini and London criteria

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 6, 2011, Pages 1064-1071

  Le Roux, Pierre Yves ^a   Gastinne, Thomas ^b   Le Gouill, Steven ^b   Nowak, Emmanuel ^c   Bodet Milin, Caroline ^b   Querellou, Solène ^a   Mahe, Beatrice ^b   Dubruille, Viviane ^b   Blin, Nicolas ^b   Salaun, Pierre Yves ^a   Bodere Kraeber, Françoise ^b  

^a BREST UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Centre d'Investigation Clinique   (France)

Author keywords

Assessment criteria; Hodgkin's lymphoma; Interim FDG PET CT; Response adapted strategy

Indexed keywords

BLEOMYCIN; CARMUSTINE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958067512     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1741-0     Document Type: Article

References (23)

1. V Bonfante A Santoro S Viviani P Valagussa G Bonadonna 1992 ABVD in the treatment of Hodgkin's disease Semin Oncol 19 2 Suppl 5 38 44 1384143 1:STN:280:DyaK3s%2FjtVyrtA%3D%3D
2. GP Canellos JR Anderson KJ Propert N Nissen MR Cooper ES Henderson, et al. 1992 Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med 327 21 1478 1484 1383821 10.1056/ NEJM199211193272102 1:STN:280:DyaK3s%2FisVyisQ%3D%3D
3. DB Duggan GR Petroni JL Johnson JH Glick RI Fisher JM Connors, et al. 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial J Clin Oncol 21 4 607 614 12586796 10.1200/JCO.2003.12.086 1:CAS:528:DC%2BD2cXpsVGrtbg%3D (Pubitemid 46621893)
4. BM Aleman AW van den Belt-Dusebout WJ Klokman MB Van't Veer H Bartelink FE van Leeuwen 2003 Long-term cause-specific mortality of patients treated for Hodgkin's disease J Clin Oncol 21 18 3431 3439 12885835 10.1200/JCO.2003.07.131 (Pubitemid 46603515)
5. A Josting S Wiedenmann J Franklin M May M Sieber J Wolf, et al. 2003 Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group J Clin Oncol 21 18 3440 3446 12668650 10.1200/JCO.2003.07.160 (Pubitemid 46594076)
6. D Hasenclever V Diehl 1998 A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med 339 21 1506 1514 9819449 10.1056/NEJM199811193392104 1:STN:280:DyaK1M%2FisFenuw%3D%3D (Pubitemid 28543499)
7. M Hutchings NG Mikhaeel PA Fields T Nunan AR Timothy 2005 Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Ann Oncol 16 7 1160 1168 15939713 10.1093/annonc/mdi200 1:STN:280:DC%2BD2Mzmslykug%3D%3D (Pubitemid 41418320)
8. M Hutchings A Loft M Hansen LM Pedersen T Buhl J Jurlander, et al. 2006 FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma Blood 107 1 52 59 16150944 10.1182/blood-2005-06-2252 1:CAS:528:DC%2BD28XhsVGgsg%3D%3D (Pubitemid 43053523)
9. PL Zinzani M Tani S Fanti L Alinari G Musuraca E Marchi, et al. 2006 Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann Oncol 17 8 1296 1300 16766583 10.1093/annonc/mdl122 1:STN:280:DC%2BD28rivFSrtQ%3D%3D (Pubitemid 44288221)
10. A Gallamini M Hutchings L Rigacci L Specht F Merli M Hansen, et al. 2007 Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study J Clin Oncol 25 24 3746 3752 17646666 10.1200/JCO.2007.11.6525 1:CAS:528:DC%2BD2sXhtVeqt7fE (Pubitemid 47372616)
11. SF Barrington W Qian EJ Somer A Franceschetto B Bagni E Brun, et al. 2010 Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma Eur J Nucl Med Mol Imaging 37 10 1824 1833 20505930 10.1007/s00259-010-1490-5
12. ME Juweid S Stroobants OS Hoekstra FM Mottaghy M Dietlein A Guermazi, et al. 2007 Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 5 571 578 17242397 10.1200/JCO.2006.08.2305 (Pubitemid 350002965)
13. M Meignan A Gallamini C Haioun 2009 Report on the First International Workshop on Interim-PET-Scan in Lymphoma Leuk Lymphoma 50 8 1257 1260 19544140 10.1080/10428190903040048
14. A Gallamini F Fiore R Sorasio M Meignan 2009 Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation Leuk Lymphoma 50 11 1761 1764 19883305 10.3109/ 10428190903308072
15. BD Cheson SJ Horning B Coiffier MA Shipp RI Fisher JM Connors, et al. 1999 Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 4 1244 10561185 1:STN:280:DC%2BD3c%2FivF2itg%3D%3D
16. BD Cheson B Pfistner ME Juweid RD Gascoyne L Specht SJ Horning, et al. 2007 Revised response criteria for malignant lymphoma J Clin Oncol 25 5 579 586 17242396 10.1200/JCO.2006.09.2403 (Pubitemid 350002966)
17. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
18. R Peto MC Pike P Armitage NE Breslow DR Cox SV Howard, et al. 1977 Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II, analysis and examples Br J Cancer 35 1 1 39 831755 10.1038/bjc.1977.1 1:STN:280:DyaE2s%2FoslGmsQ%3D%3D (Pubitemid 8018922)
19. T Terasawa J Lau S Bardet O Couturier T Hotta M Hutchings, et al. 2009 Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review J Clin Oncol 27 11 1906 1914 19273713 10.1200/JCO.2008.16.0861
20. M Hutchings SF Barrington 2009 PET/CT for therapy response assessment in lymphoma J Nucl Med 50 Suppl 1 21S 30S 19380407 10.2967/jnumed.108.057190 1:CAS:528:DC%2BD1MXmtFahsbw%3D
21. J Markova C Kobe M Skopalova K Klaskova K Dedeckova A Plütschow, et al. 2009 FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value Ann Oncol 20 7 1270 1274 19228806 10.1093/annonc/ mdn768 1:STN:280:DC%2BD1MvivFaitw%3D%3D
22. EJ Dann R Bar-Shalom A Tamir R Epelbaum I Avivi M Ben-Shachar, et al. 2010 A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma Haematologica 95 7 1198 1206 20410186 10.3324/haematol.2009.016105
23. M Meignan 2010 Interim PET in lymphoma: a step towards standardization Eur J Nucl Med Mol Imaging 37 1821 1823 20652564 10.1007/s00259-010-1546-6